Dolutegravir more likely to suppress very high viral loads than other recommended first-line drugs
One in three people starting treatment had a viral load above 100,000 copies, large US study finds People with very high pre-treatment viral loads who took dolutegravir were significantly less likely to have experienced treatment failure nine months after starting treatment compared to people taking other drugs recommended for first-line treatment, a review of more… Read More »